Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab

Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab

Bibliographic Details
Main Authors:	Shuguang Tan, Kefang Liu, Yan Chai, Catherine W.-H. Zhang, Shan Gao, George F. Gao, Jianxun Qi
Format:	Article
Language:	English
Published:	SpringerOpen 2017-05-01
Series:	Protein & Cell
Online Access:	http://link.springer.com/article/10.1007/s13238-017-0412-8

Similar Items

Crystal clear: visualizing the intervention mechanism of the PD-1/PD-L1 interaction by two cancer therapeutic monoclonal antibodies
by: Shuguang Tan, et al.
Published: (2016-11-01)

Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma
by: Faiena I, et al.
Published: (2018-01-01)

The FG Loop of PD-1 Serves as a “Hotspot” for Therapeutic Monoclonal Antibodies in Tumor Immune Checkpoint Therapy
by: Danqing Chen, et al.
Published: (2019-04-01)

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab
by: Hyun Tae Lee, et al.
Published: (2017-07-01)

Limited Cross-Linking of 4-1BB by 4-1BB Ligand and the Agonist Monoclonal Antibody Utomilumab
by: Yan Li, et al.
Published: (2018-10-01)

Durvalumab activity in previously treated patients who stopped durvalumab without disease progression
by: Siddharth Sheth, et al.
Published: (2020-07-01)

An unexpected N-terminal loop in PD-1 dominates binding by nivolumab
by: Shuguang Tan, et al.
Published: (2017-02-01)

Monoclonal Antibodies as Neurological Therapeutics
by: Panagiotis Gklinos, et al.
Published: (2021-01-01)

Therapeutic monoclonal antibody for Sporotrichosis
by: Sandro eAlmeida
Published: (2012-11-01)

Monoclonal antibodies as potent therapeutics in dentistry.
by: Pratichi Tripathi, et al.
Published: (2019-05-01)

In vivo characterization of therapeutic monoclonal antibodies
by: Xiaobin Xu
Published: (2016-01-01)

The pharmacology and therapeutic applications of monoclonal antibodies
by: María Sofía Castelli, et al.
Published: (2019-12-01)

Determining the binding affinity of therapeutic monoclonal antibodies towards their native unpurified antigens in human serum.
by: Christine Bee, et al.
Published: (2013-01-01)

Retinal Vasculitis Secondary to Durvalumab
by: Antonio R. Andrade, et al.
Published: (2020-05-01)

Safety and activity of the TGFβ receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer
by: Antoine Hollebecque, et al.
Published: (2021-03-01)

Therapeutic Uses of Monoclonal Antibodies for COVID-19
by: Tarun Kumar Suvvari
Published: (2020-01-01)

The combination of anti-KIR monoclonal antibodies with anti-PD-1/PD-L1 monoclonal antibodies could be a critical breakthrough in overcoming tumor immune escape in NSCLC
by: He YY, et al.
Published: (2018-04-01)

Binding of omeprazole to protein targets identified by monoclonal antibodies.
by: Naw May Pearl Cartee, et al.
Published: (2020-01-01)

Binding of omeprazole to protein targets identified by monoclonal antibodies
by: Naw May Pearl Cartee, et al.
Published: (2020-01-01)

Studies on the binding conditions of monoclonal antibody with colloidal gold
by: Kuo,Ying-Mao, et al.
Published: (2015)

Study on the biological functions and binding proteins of anti-dsDNA monoclonal antibody
by: Yu-Shan Wang, et al.
Published: (1999)

Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential
by: Baldini C, et al.
Published: (2019-04-01)

Review of the Combination Strategies Used in Anti-PD1/PD-L1 Monoclonal Antibody Treatment
by: Cheng Jiaxing
Published: (2020-01-01)

Distinct expression profiles of Notch-1 protein in human solid tumors: Implications for development of targeted therapeutic monoclonal antibodies
by: Yuan Li, et al.
Published: (2010-06-01)

Crystal structure of the African swine fever virus core shell protein p15
by: Kefang Liu, et al.
Published: (2021-04-01)

The Therapeutic Potential of Anti-Interleukin-20 Monoclonal Antibody
by: Yu-Hsiang Hsu, et al.
Published: (2014-05-01)

Monoclonal Antibodies Targeting Ion Channels and Their Therapeutic Potential
by: Aurélien Haustrate, et al.
Published: (2019-06-01)

Advances and challenges in therapeutic monoclonal antibodies drug development
by: Mariana Lopes dos Santos, et al.
Published: (2018-11-01)

Therapeutic Potential of Inorganic Nanoparticles for the Delivery of Monoclonal Antibodies
by: Christopher T. Turner, et al.
Published: (2015-01-01)

Recent progress in the molecular imaging of therapeutic monoclonal antibodies
by: Kaifeng He, et al.
Published: (2020-10-01)

The Role of Fc Receptors on the Effectiveness of Therapeutic Monoclonal Antibodies
by: Patricia Gogesch, et al.
Published: (2021-08-01)

Preclinical Characterization of GLS-010 (Zimberelimab), a Novel Fully Human Anti-PD-1 Therapeutic Monoclonal Antibody for Cancer
by: Beilei Lou, et al.
Published: (2021-09-01)

Development of canine PD-1/PD-L1 specific monoclonal antibodies and amplification of canine T cell function.
by: Jin Wook Choi, et al.
Published: (2020-01-01)

Disorder of Coagulation-Fibrinolysis System: An Emerging Toxicity of Anti-PD-1/PD-L1 Monoclonal Antibodies
by: Ryo Sato, et al.
Published: (2019-05-01)

Clinical Research Progress of Anti PD-1/PD-L1 Monoclonal Antibody in the Treatment of Lung Cancer
by: Zhiyu HUANG, et al.
Published: (2015-11-01)

Optimal PD-L1-high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy.
by: Magdalena Zajac, et al.
Published: (2020-01-01)

Skin puckering and edema during durvalumab therapy
by: Brianna Olamiju, BA, et al.
Published: (2021-01-01)

Durvalumab in NSCLC: latest evidence and clinical potential
by: Nerea Muñoz-Unceta, et al.
Published: (2018-10-01)

Durvalumab-induced diabetic ketoacidosis followed by hypothyroidism
by: Shivani Patel, et al.
Published: (2019-12-01)

Phimosis: A rare complication of immunotherapy with durvalumab
by: Luis Gabriel Vázquez-Lavista, et al.
Published: (2020-11-01)